A Methodology Study To Look At Genes In Lung Cells And Tissue From Asthmatic Patients

Asthma Clinical Trial

Official title:

A Study to Identify a Transcriptomic Profile Indicative of Cycle AMP Pathway Activation in the Lung

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00331292
• Other study ID #: CRB100706
• Status: Terminated
• Phase: N/A
• First received: May 26, 2006
• Last updated: October 15, 2008
• Start date: August 2006

Study information

• Verified date: October 2008
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

The primary goal of this study is to identify a gene or panel of genes which are differentially expressed in lung cells and tissue from asthmatic patients following administration of Ipratropium bromide and eiTher nebulised Albuterol or saline. Each subject in this study will undergo two bronchoscopies.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 30
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 45 Years

Eligibility

Inclusion criteria:

• Have a history of intermittant asthma.

• Have asthma symptoms less than once per week.

• Have no other significant disease.

• Do not take regular oral or inhaled steroids.

• Are a non-smoker for the past 12 months with a pack history of less than 5 years.

Exclusion criteria:

• Have a history of drug or alcohol abuse.

• Have poorly controlled asthma or a history of life-threatening asthma.

• Have a history of hypersensitivity to bronchodilators.

• Are unable to abstain from inhaled steroids from 14 days prior to the first study visit until completion of the study.

• Have received oral steroids within 3 months of study entry.

• Have been hospitalized for your asthma within 3 months of study entry.

• Have had treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Asthma

Locations

Country	Name	City	State
United States	GSK Investigational Site	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United States,